Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy, characterized by abnormal proliferation of progenitor cells. Age is a fundamental risk factor, with median overall survival (OS) <6 months for elderly patients with AML receiving intensive therapy [1]. Several measurable and immeasurable factors, including poor performance status, adverse cytogenetics, genetic mutations, and complications, are responsible for poor prognosis [2][3][4][5].
Introduction
Granulocyte colony-stimulating factor (G-CSF) priming induced G0/ G1 phase leukemia cells into an S phase, enhancing cell response to DAC. Then, DAC (15 mg/m 2 D1-5) plus CAG (termed D-CAG, comprising Ara-C [10 mg/m 2 , q12h, D3-9], aclarubicin [10 mg/day, D3-6], and G-CSF [300 µg/day, D0-9]) was designed to treat older AML patients [18] . Overall response rate (ORR) was achieved by 70 patients (82.4%), and CR was 64.7% after the first cycle. The median OS for all patients was 10 months (1-42 months), with a 1-year OS probability of 46.23%. This regimen was well tolerated, with induction mortality of only 4.4%. The results verified that the D-CAG regimen was superior to DAC monotherapy when compared with historical data.
Homoharringtonine (HHT), an alkaloid from Chinese natural plants, was considered a potential treatment for leukemia. Geng et al. [19] verified the enhanced effect of DAC plus HHT for inhibiting the viability of AML-derived Kg-1a cells. In a randomized Chinese study, the CR rate was statistically different between three treatment arms (DAC it was also closely related to the treatment cycles of SC-MCT. This regimen was well tolerated, with rare nonhematological toxicities.
Early mortality (within 1 month) was only 4.3%, and no graft versus host disease (GVHD) was observed.
Lenalidomide, an immunomodulatory agent, is capable of regulating gene expression and phosphatase activity [24] . The combination therapy of sequential AZA and lenalidomide demonstrated encouraging clinical activity in previously untreated elderly AML patients [25] . In a phase II study, 52 older untreated patients were administered with AZA 75 mg/m 2 D1-7, followed by escalating doses (5 mg, 10 mg, 25 mg, and 50 mg) of lenalidomide D8-28 of each cycle every 6 weeks [26] . The ORR was 40%, but the median OS was 5 months. Median OS was longer for responders compared with nonresponders (17.25 versus 3.75 months). The combination therapy led to limited grade ≥ 3 toxicities and an early mortality of 17%. Another phase II study reported the outcome of a combination regimen in poor-risk previously treated elderly AML patients [27] . After a median of two treatment cycles (1-11), the response rate was 25%, and responders showed a greater survival advantage. Neutropenic fever was the most common serious AE.
To summarize, the combination of HMAs with immunotherapy enhanced the antileukemic effect over a single regimen, and it was considered effective and safe for elderly AML patients, especially untreated ones.
Combined with histone deacetylase inhibitors
Histone deacetylase inhibitors (HDACis) have been proven to induce leukemia cell differentiation and prevent proliferation via blocking the cell cycle at the G1 phase [28] . Current published HDACis include valproic acid (VPA), vorinostat, entinostat, and panobinostat.
VPA, a short-chained fatty acid, was demonstrated to promote growth inhibition, apoptosis induction, and reactivation of p57KIP2 and p21CIP1 in leukemic cell lines HL-60 and MOLT4 when combined with DAC [29] . However, in vivo, the combination regimen did not show antileukemia activity. A phase 1/2 and a phase 1 study revealed that the addition of VPA led to neurotoxicity, whose severity depended on the dose [30, 31] . A phase II study compared the efficacy and safety of DAC monotherapy with the combination therapy [32] . Among 62 patients with AML, 58 (93.5%) were aged ≥ 60 years. A statistically higher CR rate and an approximate 2-month modest improvement of the median OS were observed in the DAC monotherapy arm. The incidence of AEs was higher with the combination arm, particularly neurotoxicity. This unfavorable outcome may be due to the use of a particularly weak HDACi and the administration scheduling.
VPA, AZA, plus all-trans-retinoic acid (ATRA) were also evaluated as induction therapies. The result from a phase 1/2 study was favorable, with a response rate of 52% for elderly patients with untreated AML [33] . A phase II study enrolling 65 patients with median age of 72 years (50-87 years) revealed that the best responses were 14 CR and 3 PR (26%). Median OS was 12.4 months for the whole cohort and
months for the untreated AML/myelodysplastic syndrome (MDS)
group [34] . The use of HDACi was considered to restore sensitivity to ATRA, and AZA could enhance the activity of ATRA, inducing hypomethylation and reexpression of the retinoic acid receptorbeta2 (RAR-b2) gene [35, 36] . It is feasible that the combination of HMAs with HDACi sensitizes ATRA-resistant AML to the effects of ATRA. Vorinostat, an orally administered synthetic HDACi, has a dual ability of inhibiting both histone and protein deacetylase. A phase I dose-escalation study determined the maximum administered dose (MAD) of DAC and vorinostat at 20 mg/m 2 for 5 days and 400 mg/day for 14 days, respectively. For untreated AML, patients receiving concurrent therapy showed a higher response rate (46% versus 14%) compared to those with sequential therapy. However, more serious AEs were reported in the concurrent arm [37] .
Panobinostat, a pan-HDACi, was combined with AZA for AML and high-risk MDS patients unfit for intensive chemotherapy [38] . Taken together, it is suggested that epigenetic therapy of AML using
HDACi and HMAs warrants further investigation. The result from an in vitro study designed by Momparler et al. [40] showed that a triple combination of DNA methylation, histone methylation, and histone deacetylation induced a remarkable synergistic antineoplastic effect against human AML cells, providing a possible better treatment platform.
Combined with monoclonal antibodies
Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody, was shown to be effective in elderly AML patients. The showed a CR rate of > 30% and similar median OS of 11 months.
The early mortality rate was 7.2% and 13%, respectively. The results demonstrated that this combination therapy was a possible option for elderly patients, especially poor-risk patients. Walter et al. [43] reported the efficacy and safety of GO, AZA, plus vorinostat for elderly patients with relapsed/refractory AML. The results of an MAD schedule of GO 3 mg/m 2 D4-8, vorinostat 400 mg/day D1-9, and AZA 75 mg/m 2 D1-7 yielded a CR rate of 23.3%. Responders lived longer than those who failed therapy but lived at least 1 month (7.48 months versus 3.17 months). The treatment was well tolerated, with 1-month mortality rate of 9.3%.
Combined with kinase inhibitors

FLT3 tyrosine kinase inhibitor
AML with internal tandem duplication (ITD) mutations in the FLT3 kinase gene (FLT3/ITD) frequently predicted poor prognosis. Chang et al. [44] verified that a combination therapy of FLT3 inhibitor and
HMAs confers synergistic antileukemic effects on cell apoptosis, differentiation, and growth inhibition, which provides a novel therapeutic approach.
Midostaurin (MS)
, an oral inhibitor, had shown a therapeutic effect for wild-type and mutated FLT3 AML [45] . Superior anti-AML activity was displayed in cultured and primary FLT3-ITD-expressing AML cells administered with sequential treatment with DAC and MS [46] .
A phase I study testing the efficacy and safety of AZA plus MS verified modest clinical activity [47] . Of 14 available patients, three patients achieved CR and two patients achieved hematology improvement.
The median OS was 6 months.
Sorafenib, another FLT3 inhibitor, was applied to FLT-3-mutant AML cells MV4-11 in association with a DAC in vitro experiment [48] . The treatment significantly improved growth inhibition relative to either agent alone. In a phase II study, relapse/refractory or elderly AML patients received AZA at a dose of 75 mg/m 2 for 7 days and sorafenib 400 mg twice daily. The modest outcome was a response rate of 46%
and CR of 27% [49] .
combination therapy provides a good treatment platform. Attractive outcomes have been obtained using a combination of HMAs with CAG chemotherapy, immunomodulatory therapy, monoclonal antibodies, and proteasome inhibitors, with other regimens warranting further investigation.
